Core Viewpoint - China Resources Biopharma (华润医药) announced a significant decline in the net profit of its subsidiary, China Resources Boya Biopharma (华润博雅生物), for the fiscal year ending December 31, 2025, primarily due to market challenges and the impact of acquisitions [1][2] Group 1: Financial Performance - The net profit attributable to shareholders of China Resources Boya Biopharma is expected to be approximately RMB 105 million to RMB 136.5 million, a substantial decrease from RMB 397 million in the previous year [1] - The expected net loss, after excluding non-recurring items, is projected to be between RMB 7.5 million and RMB 15 million, compared to a net profit of RMB 302 million in the prior year [1] - The anticipated impact of non-recurring items on net profit is about RMB 120 million, influenced by government subsidies, asset sales, and wealth management income [2] Group 2: Business Challenges - The decline in net profit is largely attributed to a downturn in the market for hyaluronic acid products distributed by Anhui Greenke Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Green Cross Hong Kong Holdings, which was acquired in November 2024 [2] - The acquisition of Green Cross Hong Kong Holdings has led to impairment losses on intangible assets and goodwill totaling approximately RMB 300 million [2] - The blood products business of China Resources Boya Biopharma has faced challenges due to expanded centralized procurement, DRG/DIP reforms, medical insurance cost controls, and increased regulatory scrutiny, resulting in reduced clinical prescriptions and demand [2] Group 3: Strategic Initiatives - China Resources Boya Biopharma is committed to implementing the "1246" model and is focusing on "four remolds" (value remolding, business remolding, organizational remolding, and spiritual remolding) to navigate the complex market environment [1] - The company anticipates a year-on-year increase in operating revenue of 10% to 25%, primarily driven by the acquisition of Green Cross Hong Kong Holdings [1]

（记者 曾健辉） 每经头条（nbdtoutiao）——中国无人驾驶"军团"，"武装"阿布扎比 每经AI快讯，特宝生物1月30日晚间发布公告称，厦门特宝生物工程股份有限公司于近日收到国家药品 监督管理局核准签发的关于公司注射用ACT100系统性红斑狼疮适应症和皮肤型红斑狼疮适应症的《药 物临床试验批准通知书》。 ...

Core Viewpoint - The company Baillie Gifford Tianheng forecasts a significant decline in its 2025 performance, with expected revenue dropping by approximately 57.06% year-on-year, alongside substantial net losses attributed to increased R&D investments and lower milestone income compared to the previous year [1] Financial Performance - The company anticipates achieving an operating revenue of around 2.5 billion yuan in 2025, reflecting a year-on-year decrease of about 57.06% [1] - The projected net loss attributable to the parent company is expected to be around 1.1 billion yuan, representing a year-on-year increase of approximately 129.67% [1] - The net loss attributable to the parent company, after excluding non-recurring gains and losses, is forecasted to be around 1.2 billion yuan, indicating a year-on-year increase of about 133.01% [1] R&D Investment - The performance decline is primarily due to the company's continuous increase in R&D investment, which has seen a significant year-on-year growth [1] - The previous year's financial results included higher income from intellectual property due to a first payment from BMS, which was not matched by the milestone income recognized in the current reporting period [1]

北京商报讯（记者 王寅浩 宋雨盈）1月30日，科兴制药发布2025年业绩预告，预计2025年实现归属于母 公司所有者的净利润为1.35亿—1.75亿元，同比增加328.83%—455.89%。预计归属于母公司所有者的扣 除非经常性损益的净利润为5000万—7000万元，同比增加41.83%—98.56%。 根据公告，2025年，科兴制药积极开拓海外市场，实现了海外收入增长，推动营收持续增长，归属于母 公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提升。 ...

Group 1 - The core viewpoint of the article is that Junshi Bioscience expects a reduction in net loss for the year 2025, projecting a net loss of approximately 873 million yuan, which is a decrease of about 408 million yuan compared to the previous year, representing a year-on-year reduction of approximately 31.85% [1] - The main reason for the change in performance is attributed to an increase in operating revenue, primarily driven by the growth in sales revenue of commercialized drugs compared to the same period last year [1] Group 2 - The article highlights a surge in nuclear power construction, indicating that equipment manufacturers are extremely busy, with orders scheduled until 2028, and employees working in three shifts with production lines operating 24 hours a day [1]

本年度，公司核心产品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成为业绩核心增长引擎； 同时，公司成功达成重磅合作，授予Vor Biopharma Inc泰它西普除大中华区以外全球范围内的独家开发 与商业化权利，技术授权收入大幅增加，部分海外研发投入由授权方承担。此外，公司通过优化管理、 迭代生产工艺等举措，降低了产品单位生产成本，提升了产品毛利率，另外，销售费用率明显下降。综 合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。 格隆汇1月30日丨荣昌生物(688331.SH)公布，经公司财务部门初步测算，预计2025年度营业收入约 325,000万元，与上年同期相比，将增加收入约153,314万元，同比增加约89%。公司预计2025年度实现 归属于母公司所有者的净利润约71,600万元，与上年同期相比，实现扭亏为盈。公司预计2025年度归属 于母公司所有者扣除非经常性损益后的净利润约7,850万元，与上年同期相比，实现扭亏为盈。 ...

Core Viewpoint - Newnow (SZ300765, market value of 54.6 billion yuan) appointed a new general manager and board secretary, both born in the 1990s, which led to a negative market reaction, with the stock price dropping by up to 18% on January 30. Additionally, the company announced a significant expected loss for 2025, with net profit projected to decline by 416% to 575% compared to 2024 [1][11]. Management Changes - On January 30, Newnow announced the resignation of general manager Yao Bing and board secretary Dai Long, with Dai Long being appointed as the new general manager and Xu Wen as the new board secretary [1][13]. - Yao Bing, born in May 1977, will continue as chairman after stepping down as general manager. His pre-tax compensation for 2024 was 538,400 yuan [4][16]. - Dai Long, born in June 1992, has held various positions within the company since December 2016, including financial manager and board secretary. His pre-tax compensation for 2024 was 223,200 yuan [6][18]. - Xu Wen, born in April 1990, has been appointed as a board member since May 2024, but received no compensation from the company for 2024 [6][18]. Financial Performance - Newnow's main business focuses on biopharmaceuticals and functional foods, with a significant decline in performance expected for 2025. The company forecasts a net loss of 170 million to 255 million yuan, a decrease of 416% to 575% compared to 2024 [9][21]. - The projected net profit for 2025, excluding non-recurring items, is expected to be a loss of 210 million to 315 million yuan, representing a decline of 596% to 844% from the previous year [10][22]. - The reasons for the expected decline include increased R&D expenses due to progress in multiple products, losses from the acquisition of a controlling stake in Giant Bio, and reduced profit margins in the functional raw materials business [21][22]. - Newnow's net profits for the years 2022 to 2024 were 726 million yuan, 434 million yuan, and 53.726 million yuan, respectively, indicating a trend of significant decline over three consecutive years [21][22].

每经AI快讯，首药控股1月30日晚间发布2025年年度业绩快报，营业收入866.76万元，同比增加 119.88%；归属于上市公司股东的净利润亏损约1.29亿元；基本每股收益亏损0.87元。 （记者 曾健辉） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

Group 1 - Microchip Biotech announced on January 30 that it received a notice from shareholder Tianfu Qingkong regarding the unfreezing of approximately 8.21 million shares that were previously judicially frozen [1] Group 2 - The nuclear power construction industry is experiencing a surge in demand, with equipment manufacturers reporting that orders are booked until 2028, leading to continuous operations with employees working in three shifts around the clock [1]

Core Viewpoint - Changchun Gaoxin (000661.SZ) expects a significant decline in net profit attributable to shareholders for 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 150 million to 220 million yuan for 2025, indicating a substantial decline from the previous year [1] - The expected decline in profit is attributed to increased research and development expenses as the company advances its product pipeline [1] Group 2: Business Focus and Strategy - The company continues to focus on traditional strengths in endocrine metabolism and women's health, while also exploring innovative directions related to oncology, respiratory, and immune-related products [1] - Ongoing R&D efforts are aimed at developing differentiated products with global market potential, with several products entering clinical stages [1] Group 3: Industry Challenges - The company faces intensified competition within the industry, which is expected to impact its financial performance [1] - Changchun Baike Biotechnology Co., a subsidiary, is projected to incur losses in 2025, contributing to the overall decrease in the company's performance [1]